FITC标记的磷酸化原癌基因c-Met抗体
产品名称： FITC标记的磷酸化原癌基因c-Met抗体
英文名称： Anti-phospho-Met (Tyr1230 + Tyr1234 + Tyr1235)/FITC
产品编号： HZ-18800R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： ICC=1:50-200 IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-phospho-Met (Tyr1230 + Tyr1234 + Tyr1235)/FITC Conjugated antibody
FITC标记的磷酸化原癌基因c-Met抗体
| 英文名称 | Anti-phospho-Met (Tyr1230 + Tyr1234 + Tyr1235)/FITC |
| 中文名称 | FITC标记的磷酸化原癌基因c-Met抗体 |
| 别 名 | Met (c-Met) (phospho Y1230 + Y1234 + Y1235); Met (phospho Y1230 + Y1234 + Y1235); c-Met (phospho Y1230 + Y1234 + Y1235); AUTS9; c met; cmet; D249; Hepatocyte growth factor receptor; Hepatocyte growth factor receptor Precursor; HGF; HGF receptor; HGF SF receptor; HGF/SF receptor; HGFR; MET; Met proto oncogene tyrosine kinase; Met proto-oncogene (hepatocyte growth factor receptor); Met proto-oncogene; Met protooncogene; MET_HUMAN; Oncogene MET; Par4; Proto-oncogene c-Met; RCCP2; Renal cell carcinoma papillary 2 gene; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 肿瘤 细胞生物 信号转导 激酶和磷酸酶 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, Horse, |
| 产品应用 | ICC=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 153kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human Met around the phosphorylation site of Tyr1230 + Tyr1234 + Tyr1235 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] Function: Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival. Subcellular Location: Membrane. Post-translational modifications: Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. DISEASE: Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. Note=Defects in MET may be associated with gastric cancer. Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550]. Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes. Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Contains 3 IPT/TIG domains. Contains 1 protein kinase domain. Contains 1 Sema domain. Database links: Entrez Gene: 4233 Human Entrez Gene: 17295 Mouse Entrez Gene: 24553 Rat Omim: 164860 Human SwissProt: P08581 Human SwissProt: P16056 Mouse SwissProt: P97523 Rat Unigene: 132966 Human Unigene: 86844 Mouse Unigene: 10617 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications |
原癌基因MET产物是肝细胞生长因子受体，编码酪氨酸激酶活性。初级单链前体蛋白被翻译后裂解以产生α和β亚基，这些亚基与二硫键连接形成成熟受体。MET基因的各种突变与乳头状肾癌有关。发现了两个编码不同亚型的转录变体。[ RefSeq，JUL 2008 ]